Sleep Medications Market Analysis

Sleep Medications Market Analysis

To get key market trends

  Download Free Sample

Based on type, the sleep medications market is segmented into prescription-based drugs and OTC drugs. In 2022, the prescription-based drugs segment accounted for the largest market share of 71.3% in the industry and is expected to grow at a CAGR of 6.7% by 2032. Prescription-based drugs are favored for several reasons, including their targeted effectiveness and the healthcare professionals' capacity to customize treatment to address an individual's unique sleep disorder. These prescription medications are typically more potent and can effectively manage intricate sleep disorders, offering dependable relief for individuals enduring severe or chronic sleep problems. Furthermore, the oversight and monitoring provided by healthcare providers guarantee the safe and suitable utilization of these drugs.
 

Based on drug class, the sleep medications market is segmented into benzodiazepines, antidepressants, antihistamine, sedating antipsychotics, and other drug class. The benzodiazepines drug class is expected to showcase progress at a CAGR of 6.2% by 2032, Benzodiazepines exert their effects by enhancing the activity of neurotransmitters and induce drowsiness, reducing the time it takes to fall asleep, and extend the duration of sleep. Additionally, the ability of benzodiazepines to promote relaxation and sedation, makes this drug class more useful for individuals suffering from acute or severe sleep disorders such as insomnia or anxiety-related sleep disturbances.
 

Based on sleep disorder type, the sleep medications market is segmented into insomnia, sleep apnea, restless legs syndrome, narcolepsy, sleep walking, and other sleep disorders. The sleep disorder insomnia held the largest market share of 38.7% in 2022 and is expected to grow at a CAGR of 5.8% by 2032. For instance, as per the article published by Sleep Doctor Holdings, LLC, in 2023, 50-70 million U.S. citizens are affected by insomnia every year and nearly half of the population of the U.S. have experienced insomnia symptoms at some time. Additionally, the report also stated that 237 million people globally are struggling with insomnia.
 

Based on the region, In 2022, North America sleep medications market accounted for a revenue of USD 8.3 billion, and it is expected to reach USD 15.3 billion by 2032 attributed to factors such as the fast-paced and high-stress lifestyles that many individuals lead. The demands of busy work schedules, lengthy commutes, and the presence of societal stressors such as economic pressures and competitive work environments can all contribute to sleep disturbances and insomnia. Additionally, the occurrence of key business companies in the U.S. with the growing consumer awareness associated with the products of sleep medications and sleep excellence.